Reach Us +441234923305


Hepatic Tissue Bioenergetics Is Preserved When Treated In Vitro With Atorvastatin | 23495
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Hepatic tissue bioenergetics is preserved when treated in vitro with atorvastatin

2nd International Summit on Clinical Pharmacy

Ali S Alfazari

ScientificTracks Abstracts: Clinic Pharmacol Biopharm

DOI: 10.4172/2167-065X.S1.006

The anti-hyperlipidemic agent, Atorvastatin (3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor), is commonly prescribed for its potent cholesterol lowering effects. However, elevated transaminases and potential hepatotoxicity are known adverse effects. This study investigated the in vitro effect of this agent on hepatic tissue respiration, ATP content, caspase activity, urea synthesis and histology. Liver fragments from Taylor Outbred and C57Bl/6 mice were incubated at 37?C in Krebs- Henseleit buffer continuously gassed with 95% O2:5% CO2 in the presence and absence of atorvastatin. Phosphorescence O2 analyzer that measured dissolved [O2] as a function of time was used to monitor cellular mitochondrial O2 consumption. The caspase-3 substrate N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin was used to monitor caspase activity. The rates of hepatocyte respiration (μM O2 min-1 mg-1) in untreated samples were 0.15?0.07 (n=31). The corresponding rates for samples treated with 50 nM (therapeutic concentration), 150 nM or 1.0 μM atorvastatin for ≤13 h were 0.13?0.05 (n=19), p=0.521. The contents of hepatocyte ATP (pmol-1 mg-1) in untreated samples were 40.3?14.0 and in samples treated with 1.0 μM atorvastatin for ≤4.5 h were 48.7?23.9 (p=0.7754). The concentrations of urea (mg/dL mg-1, produced over 50 min) for untreated samples were 0.061?0.020 (n=6) and for samples treated with 1.0 μM atorvastatin for ≤6 h were 0.072?0.022 (n=6), p=0.3866. Steadily, hepatocyte caspase activity and histology were unaffected by treatments with up to 1.0 μM atorvastatin for ≤6 h. Thus, the studied murine model showed preserved hepatocyte function and structure in the presence of high concentrations of atorvastatin.
Ali S Alfazari has completed his undergraduate medical degree at the United Arab Emirates University in 1999. He then pursued a formal clinical residency program in internal medicine and then gastroenterology at Dalhousie University, Halifax, NS and University of Ottawa, Ottawa, ON respectively. He is an assistant professor of medicine at the United Arab Emirates University?s Department of Medicine and attending physician in the Department of Medicine at Tawam Hospital, Al Ain, United Arab Emirates. His research interests are clinical toxicology and cancer biology.